Medpace (NASDAQ:MEDP) CEO August Troendle Sells 1,983 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 1,983 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $620.23, for a total value of $1,229,916.09. Following the transaction, the chief executive officer directly owned 545,217 shares in the company, valued at approximately $338,159,939.91. This represents a 0.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Medpace Price Performance

Shares of MEDP stock traded down $6.66 during trading on Tuesday, reaching $613.37. The company had a trading volume of 246,088 shares, compared to its average volume of 346,263. The firm’s 50 day simple moving average is $553.21 and its two-hundred day simple moving average is $492.40. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The company has a market capitalization of $17.12 billion, a PE ratio of 35.95, a PEG ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MEDP shares. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. BMO Capital Markets boosted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a report on Thursday, July 23rd. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and raised their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Leerink Partners set a $620.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $584.18.

Institutional Investors Weigh In On Medpace

Institutional investors have recently added to or reduced their stakes in the stock. BOKF NA raised its stake in Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its position in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after purchasing an additional 21 shares during the last quarter. UMB Bank n.a. boosted its stake in Medpace by 5.6% in the fourth quarter. UMB Bank n.a. now owns 450 shares of the company’s stock worth $253,000 after purchasing an additional 24 shares in the last quarter. Schulhoff & Co. Inc. boosted its stake in Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after purchasing an additional 25 shares in the last quarter. Finally, Balefire LLC grew its holdings in shares of Medpace by 6.1% during the first quarter. Balefire LLC now owns 451 shares of the company’s stock worth $217,000 after purchasing an additional 26 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.